Agendia establishes contract with Humana for coverage of MammaPrint breast cancer recurrence test

Agendia, a world leader in molecular cancer diagnostics, announced today that it has established a contract with leading insurance provider Humana to reimburse for the company's MammaPrint test. Agendia's contract with Humana expands the coverage for MammaPrint by more than 17 million lives. In November 2009, Palmetto GBA, California's Part B Medicare administrator, established coding guidelines for MammaPrint, allowing healthcare providers from across the United States to submit claims for the test. MammaPrint is the first and only FDA-cleared breast cancer recurrence test available and has been reimbursed by payors since 2008.

"Humana is dedicated to advancing excellence in healthcare delivery on behalf of its members. This commitment to quality care and patient safety has now led Humana to include MammaPrint in its medical benefit management program," said Bernhard Sixt, Chief Executive Officer of Agendia. "We are proud that Humana is offering its members coverage for the only gene expression test for breast cancer recurrence which has been cleared by the FDA."

SOURCE Agendia B.V.